Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...
Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...
This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...
The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's ...
Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly medicine initially developed as a treatment ...
Over the course of 72 weeks, Lilly tested Zepbound and Wegovy on a population of adults with obesity or patients with "at least one weight-related medical problem and without diabetes." ...
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.
beating the performance of the Medical sector with its loss of 3.78% and the S&P 500's gain of 0.22%. The investment community will be closely monitoring the performance of Eli Lilly in its ...
Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback